BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Arena Shares Continue to Soar]]>http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/http://www.bloggingstocks.com/2010/07/26/arena-shares-continue-to-soar/#commentsFiled under:

Arena Pharmaceuticals (ARNA), which soared over 10% in Monday morning trading, has set a new 52-week high of $6.75. Over the past month, Arena signed a licensing deal for its potential weight-loss drug, lorcaserin, with Japan's Eisai; released study results for the drug; and got a boost from a decision by a Food and Drug Administration panel on rival's Vivus (VVUS) drug. Arena's shares have more than doubled during that time.

The Eisai licensing deal is potentially worth about $1.3 billion. Meanwhile, the study results Arena released showed lorcaserin helped nearly half the patients lose 5% of their weight and improved their chances of keeping it off. Arena's drug did that while exhibiting a safer safety profile than either of its competitors' treatments: Vivus's Qnexa and Orexigen's (OREX) Contrave.

Continue reading Arena Shares Continue to Soar

Arena Shares Continue to Soar originally appeared on BloggingStocks on Mon, 26 Jul 2010 14:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>arenaarnaContraveinthenewslorcaserinobesityobesity drugsorexorexigenQnexavivusvvusweight lossweight loss drugsMon, 26 Jul 2010 14:30:00 EST<![CDATA[FDA Rejection Crushes Vivus]]>http://www.bloggingstocks.com/2010/07/16/vivus-fda-rejection/http://www.bloggingstocks.com/2010/07/16/vivus-fda-rejection/http://www.bloggingstocks.com/2010/07/16/vivus-fda-rejection/#commentsFiled under: , ,

Pharmaceutical company Vivus (VVUS) has lost more than half of its value in pre-market trading Friday. Unfortunately for VVUS, the Food and Drug Administration (FDA) rejected the company's Qnexa weight-loss drug late Thursday -- citing a lack of long-term safety data.

The news triggered a glut of downgrades and target price cuts, including downgrades from Brean Murray, Needham, JP Morgan, and Jefferies.

The drop for VVUS is understandable when considering that Qnexa is the company's main drug. There is a slight (ever-so-slight) glimmer of hope for VVUS, as the FDA is not obliged to follow the recommendations of its panels. Of course, the agency usually does follow the recommendations of its panels.

Continue reading FDA Rejection Crushes Vivus

FDA Rejection Crushes Vivus originally appeared on BloggingStocks on Fri, 16 Jul 2010 09:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>ArenaARNAFDAFDA approvalFDA panelinthenewsOREXOrexigenVivusvvusFri, 16 Jul 2010 09:00:00 EST<![CDATA[Analyst upgrades: GM, GMCR, OREX and NHY]]>http://www.bloggingstocks.com/2007/10/03/analyst-upgrades-gm-gmcr-orex-and-nhy/http://www.bloggingstocks.com/2007/10/03/analyst-upgrades-gm-gmcr-orex-and-nhy/http://www.bloggingstocks.com/2007/10/03/analyst-upgrades-gm-gmcr-orex-and-nhy/#commentsFiled under: , , ,

MOST NOTEWORTHY: General Motors, Green Mountain Coffee, Orexigen and Norsk Hydro were today's noteworthy upgrades:
  • Banc of America upgraded shares of General Motors Corporation (NYSE: GM) to Neutral from Sell as they believe the agreement with the United Auto Workers union offsets a worsening outlook for sales.
  • Piper Jaffray upgraded shares of Green Mountain Coffee Roasters (NASDAQ: GMCR) to Outperform from Market Perform after a meeting with management as they believe shares offer a compelling buying opportunity at current levels based on their 2009 estimates.
  • JMP Securities upgraded shares of Orexigen Therapeutics (NASDAQ: OREX) to Strong Buy from Market Outperform as they believe the company's lead product candidates, Empatic and Contrave, could become front-line therapies for obesity due to improved durability of efficacy, increased safety and tolerability, and lack of addiction.
  • Norsk Hydro (NYSE: NHY) was upgraded to Buy from Hold at Citigroup. The firm sees upside in the stock from the volume growth and further improvements in downstream operations.
OTHER UPGRADES:

Analyst upgrades: GM, GMCR, OREX and NHY originally appeared on BloggingStocks on Wed, 03 Oct 2007 10:50:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>analystciencienaeenigeneral motorsGeneralMotorsgmgmcrgreen mountainGreenMountainnhynorsk hydroNorskHydroorexorexigensmmxsymyxtemple inlandTempleInlandtinupgradeWed, 03 Oct 2007 10:50:00 EST